StreetInsider.com News Articles

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Tue, 27 Jan 2026 10:52:27 -0500

Investing.com -- Citi launched broad coverage of major European pharmaceutical companies with a mixed outlook, issuing Buy ratings on AstraZeneca and Novartis while taking a more cautious stance on GSK, Novo Nordisk and Sanofi.

Analyst Graham Parry said valuations, pipeline depth and looming loss-of-exclusivity (LOE) events shape the bank’s relative preferences for 2026 and beyond.

Citi initiated GSK at Neutral with a 1,900p target, saying the company’s “growth, margins, dividend policy, balance sheet and pipeline have all improved,” helping drive a more than 45 percent share gain in 2025.

But Parry warned that the mid-term looks difficult, noting

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Tue, 27 Jan 2026 10:52:27 -0500

Analyst Graham Parry said valuations, pipeline depth and looming loss-of-exclusivity (LOE) events shape the bank’s relative preferences for 2026 and beyond.

But Parry warned that the mid-term looks difficult, noting

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Tue, 27 Jan 2026 10:52:27 -0500

Analyst Graham Parry said valuations, pipeline depth and looming loss-of-exclusivity (LOE) events shape the bank’s relative preferences for 2026 and beyond.

But Parry warned that the mid-term looks difficult, noting

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Tue, 27 Jan 2026 10:52:27 -0500

Analyst Graham Parry said valuations, pipeline depth and looming loss-of-exclusivity (LOE) events shape the bank’s relative preferences for 2026 and beyond.

But Parry warned that the mid-term looks difficult, noting

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Tue, 27 Jan 2026 10:52:27 -0500

Analyst Graham Parry said valuations, pipeline depth and looming loss-of-exclusivity (LOE) events shape the bank’s relative preferences for 2026 and beyond.

But Parry warned that the mid-term looks difficult, noting

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Tue, 27 Jan 2026 10:52:27 -0500

Analyst Graham Parry said valuations, pipeline depth and looming loss-of-exclusivity (LOE) events shape the bank’s relative preferences for 2026 and beyond.

But Parry warned that the mid-term looks difficult, noting

Nike, UiPath gain in premarket; Intel falls

Wed, 24 Dec 2025 06:42:35 -0500

Investing.com-- U.S. equity index futures edged lower ahead of the Christmas holiday, with S&P 500 Futures down 0.1% at 6:40 ET (11:40 GMT) in New York, putting the benchmark on track to pull back from a record high.

UiPath (NYSE:PATH) shares jumped 8.3% in premarket trading on Wednesday after the company said it will be added to the S&P MidCap 400 index. The automation software firm will take the place of Synovus Financial, with the change scheduled to become effective before the opening bell on Friday, January 2.
Nike, UiPath gain in premarket; Intel falls

Wed, 24 Dec 2025 06:42:35 -0500

Investing.com-- U.S. equity index futures edged lower ahead of the Christmas holiday, with S&P 500 Futures down 0.1% at 6:40 ET (11:40 GMT) in New York, putting the benchmark on track to pull back from a record high.
UiPath (NYSE:PATH) shares jumped 8.3% in premarket trading on Wednesday after the company said it will be added to the S&P MidCap 400 index. The automation software firm will take the place of Synovus Financial, with the change scheduled to become effective before the opening bell on Friday, January 2.

Nike, UiPath gain in premarket; Intel falls

Wed, 24 Dec 2025 06:42:35 -0500

Investing.com-- U.S. equity index futures edged lower ahead of the Christmas holiday, with S&P 500 Futures down 0.1% at 6:40 ET (11:40 GMT) in New York, putting the benchmark on track to pull back from a record high.
UiPath (NYSE:PATH) shares jumped 8.3% in premarket trading on Wednesday after the company said it will be added to the S&P MidCap 400 index. The automation software firm will take the place of Synovus Financial, with the change scheduled to become effective before the opening bell on Friday, January 2.

Nike, UiPath gain in premarket; Intel falls

Wed, 24 Dec 2025 06:42:35 -0500

Investing.com-- U.S. equity index futures edged lower ahead of the Christmas holiday, with S&P 500 Futures down 0.1% at 6:40 ET (11:40 GMT) in New York, putting the benchmark on track to pull back from a record high.
UiPath (NYSE:PATH) shares jumped 8.3% in premarket trading on Wednesday after the company said it will be added to the S&P MidCap 400 index. The automation software firm will take the place of Synovus Financial, with the change scheduled to become effective before the opening bell on Friday, January 2.

Nike, UiPath gain in premarket; Intel falls

Wed, 24 Dec 2025 06:42:35 -0500

Investing.com-- U.S. equity index futures edged lower ahead of the Christmas holiday, with S&P 500 Futures down 0.1% at 6:40 ET (11:40 GMT) in New York, putting the benchmark on track to pull back from a record high.
UiPath (NYSE:PATH) shares jumped 8.3% in premarket trading on Wednesday after the company said it will be added to the S&P MidCap 400 index. The automation software firm will take the place of Synovus Financial, with the change scheduled to become effective before the opening bell on Friday, January 2.

Nike, UiPath gain in premarket; Intel falls

Wed, 24 Dec 2025 06:42:35 -0500

Investing.com-- U.S. equity index futures edged lower ahead of the Christmas holiday, with S&P 500 Futures down 0.1% at 6:40 ET (11:40 GMT) in New York, putting the benchmark on track to pull back from a record high.
UiPath (NYSE:PATH) shares jumped 8.3% in premarket trading on Wednesday after the company said it will be added to the S&P MidCap 400 index. The automation software firm will take the place of Synovus Financial, with the change scheduled to become effective before the opening bell on Friday, January 2.

Nike, UiPath gain in premarket; Intel falls

Wed, 24 Dec 2025 06:42:35 -0500

Investing.com-- U.S. equity index futures edged lower ahead of the Christmas holiday, with S&P 500 Futures down 0.1% at 6:40 ET (11:40 GMT) in New York, putting the benchmark on track to pull back from a record high.
UiPath (NYSE:PATH) shares jumped 8.3% in premarket trading on Wednesday after the company said it will be added to the S&P MidCap 400 index. The automation software firm will take the place of Synovus Financial, with the change scheduled to become effective before the opening bell on Friday, January 2.

Sanofi beats estimates on strong Dupixent sales, new drug launches; stock up

Fri, 24 Oct 2025 06:55:19 -0500

Investing.com -- Sanofi reported stronger-than-expected third-quarter results, driven by accelerating demand for its blockbuster drug Dupixent and a wave of new product launches.

Shares rose around 3% in early Paris trading after the report.

The French pharmaceutical company said Friday that net sales rose 7% year-on-year at constant exchange rates to €12.43 billion ($14.44 billion), above analyst expectations of €12.29 billion.

Business operating income stood at €4.45 billion, topping the €4.15 billion average forecast from a company-compiled survey.

Sanofi reported net profit of €2.80 billion, down 0.5% from a year earlier due to losses from discontinued operations. On an adjusted basis, business net profit rose

Sanofi beats estimates on strong Dupixent sales, new drug launches; stock up

Fri, 24 Oct 2025 06:55:19 -0500

Investing.com -- Sanofi reported stronger-than-expected third-quarter results, driven by accelerating demand for its blockbuster drug Dupixent and a wave of new product launches.

Shares rose around 3% in early Paris trading after the report.

The French pharmaceutical company said Friday that net sales rose 7% year-on-year at constant exchange rates to €12.43 billion ($14.44 billion), above analyst expectations of €12.29 billion.

Business operating income stood at €4.45 billion, topping the €4.15 billion average forecast from a company-compiled survey.

Sanofi reported net profit of €2.80 billion, down 0.5% from a year earlier due to losses from discontinued operations. On an adjusted basis, business net profit rose

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

Mon, 29 Sep 2025 07:32:27 -0500

Investing.com -- Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing prescription trends, intensifying competition, and looming pricing pressures.
Shares in Novo Nordisk fell over 3% in U.S. premarket trading Monday.
The bank’s analysts pointed to stagnation in U.S. prescriptions for key drugs Ozempic and Wegovy, as well as a steady decline for Rybelsus. While weekly volumes for Wegovy rose earlier in the year, they have held flat for the past nine weeks, suggesting limited momentum.
“The lack of momentum

StreetInsider.com News Articles

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'

Nike, UiPath gain in premarket; Intel falls

Nike, UiPath gain in premarket; Intel falls

Nike, UiPath gain in premarket; Intel falls

Nike, UiPath gain in premarket; Intel falls

Nike, UiPath gain in premarket; Intel falls

Nike, UiPath gain in premarket; Intel falls

Nike, UiPath gain in premarket; Intel falls

Sanofi beats estimates on strong Dupixent sales, new drug launches; stock up

Sanofi beats estimates on strong Dupixent sales, new drug launches; stock up

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip

M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip